CGEM

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Cullinan Therapeutics doses the first patient in the planned registrational Phase 2 trial of CLN-049 in relapsed or refractory acute myeloid leukemiaOct 8, 2026
• Cullinan Therapeutics initiates NDA submission for zipalertinib plus chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated NSCLC under the FDA Real-Time Oncology Review programOct 2, 2026
• Zipalertinib plus chemotherapy delivered a six-month median progression-free survival benefit in the Phase 3 REZILIENT3 first-line trial for EGFR exon 20 insertion-positive NSCLCSep 14, 2026
• Zipalertinib plus chemotherapy met the primary progression-free survival endpoint in an interim analysis of the Phase 3 REZILIENT3 trial in first-line EGFR exon 20 insertion-mutated non-small cell lung cancerAug 13, 2026
• Cullinan Therapeutics reports positive end-of-Phase 1 FDA meeting and advances CLN-049 toward a potentially registrational Phase 2 AML studyJul 28, 2026